These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 17103071

  • 1. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
    Prenzel KL, König A, Schneider PM, Schnickmann C, Baldus SE, Schröder W, Bollschweiler E, Dienes HP, Mueller RP, Izbicki JR, Hölscher AH.
    Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.
    Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH.
    Ann Surg; 2008 Dec; 248(6):902-8. PubMed ID: 19092334
    [Abstract] [Full Text] [Related]

  • 4. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, Zanchettin G, Rugge M, Ancona E.
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [Abstract] [Full Text] [Related]

  • 5. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.
    Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, Baldus SE, Metzger R, Hölscher AH.
    Ann Surg Oncol; 2010 Dec; 17(12):3187-94. PubMed ID: 20585867
    [Abstract] [Full Text] [Related]

  • 6. Prognostic impact of nodal micrometastasis in early esophageal cancer.
    Prenzel KL, Hölscher AH, Drebber U, Agavonova M, Gutschow CA, Bollschweiler E.
    Eur J Surg Oncol; 2012 Apr; 38(4):314-8. PubMed ID: 22277724
    [Abstract] [Full Text] [Related]

  • 7. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
    Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP, Hoelscher AH.
    Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
    [Abstract] [Full Text] [Related]

  • 8. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV.
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [Abstract] [Full Text] [Related]

  • 9. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM.
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
    Saha AK, Sutton C, Rotimi O, Dexter S, Sue-Ling H, Sarela AI.
    Ann Surg Oncol; 2009 May; 16(5):1364-70. PubMed ID: 19252949
    [Abstract] [Full Text] [Related]

  • 11. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP.
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [Abstract] [Full Text] [Related]

  • 12. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D, Kuhn E, Warnecke-Eberz U, Brabender J, Hoffmann AC, Metzger R, Baldus SE, Drebber U, Hoelscher AH, Schneider PM.
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [Abstract] [Full Text] [Related]

  • 13. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
    Narumiya K, Metzger R, Bollschweiler E, Alakus H, Brabender J, Drebber U, Hölscher AH, Warnecke-Eberz U.
    Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
    [Abstract] [Full Text] [Related]

  • 14. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH.
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [Abstract] [Full Text] [Related]

  • 15. Clinical implications of lymph node micrometastasis in patients with histologically node-negative (pN0) esophageal carcinoma.
    Nakamura T, Ide H, Eguchi R, Hayashi K, Ota M, Takasaki K.
    J Surg Oncol; 2002 Apr; 79(4):224-9. PubMed ID: 11920779
    [Abstract] [Full Text] [Related]

  • 16. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
    Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, Nishida T, Mano M, Mori M, Doki Y.
    Cancer; 2009 Jul 15; 115(14):3324-34. PubMed ID: 19452547
    [Abstract] [Full Text] [Related]

  • 17. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.
    Mariette C, Piessen G, Briez N, Triboulet JP.
    Ann Surg; 2008 Feb 15; 247(2):365-71. PubMed ID: 18216546
    [Abstract] [Full Text] [Related]

  • 18. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR.
    Cancer; 2006 May 15; 106(10):2119-27. PubMed ID: 16607651
    [Abstract] [Full Text] [Related]

  • 19. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
    Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ.
    Cancer; 2007 Jan 01; 109(1):125-34. PubMed ID: 17146785
    [Abstract] [Full Text] [Related]

  • 20. Accurate lymph node assessment prior to trimodality therapy for esophageal carcinoma.
    Suntharalingam M, Haas ML, Sonett JR, Doyle LA, Hausner PF, Schuetz J, Greenwald B, Krasna MJ.
    Cancer J; 2001 Jan 01; 7(6):509-15. PubMed ID: 11769864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.